

# Explore the expanding Amneal Biosciences portfolio

We deliver high-quality, essential medicines. To increase choice, access, and affordability, we have expanded our offerings to include **biosimilars and ready-to-use oncology injectables**.<sup>1</sup>

## Biosimilar products

The logo for Alymsys, featuring the word "Alymsys" in a bold, lowercase sans-serif font with a blue bar chart icon above the "y", and "(bevacizumab-maly)" in a smaller font below.

The logo for Fylnetra, featuring the word "Fylnetra" in a bold, lowercase sans-serif font with a blue bar chart icon above the "t", and "(pegfilgrastim-pbbk)" in a smaller font below.

The logo for Releuko, featuring the word "Releuko" in a bold, lowercase sans-serif font with a blue bar chart icon above the "o", and "(filgrastim-ayow)" in a smaller font below.

## Ready-to-use oncology injectables

The logo for FOCINVEZ, featuring a stylized blue and orange arrow icon to the left of the word "FOCINVEZ" in a bold, uppercase sans-serif font, with "(fosaprepitant injection)" in a smaller font below.

The logo for PEMRYDI RTU, featuring the word "PEMRYDI" in a bold, uppercase sans-serif font with a yellow and orange underline, followed by "RTU" in a smaller font, and "(pemetrexed injection)" in a smaller font below.

The logo for BORUZU, featuring a colorful molecular structure icon above the word "BORUZU" in a bold, uppercase sans-serif font, and "(bortezomib injection)" in a smaller font below.

Please see back cover for trademark attributions.





FDA-approved biosimilars: Increasing access while lowering cost

A biosimilar is a therapeutic product that the FDA has determined to be highly similar to an approved biologic and has no clinical differences in terms of safety and effectiveness.<sup>2</sup>

Ready-to-use oncology injectables: Supporting operational efficiency

The 505(b)(2) FDA regulatory approval pathway allows for enhancements in product characteristics that may support operational efficiency, such as simplified storage and preparation.<sup>8</sup>

ALYMSYS® (bevacizumab-maly)

Reference product: Avastin® (bevacizumab)<sup>3</sup>

Description: Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg<sup>4</sup>

- Diluted solution can be stored for up to 12 hours at 2°C to 8°C (36°F to 46°F)<sup>3</sup>
- Extended shelf life of up to 30 months in unopened vial<sup>5</sup>

Unit of sale <sup>3</sup>	Unit of sale quantity	NDC
100 mg/4 mL	1 vial	70121-1754-1
100 mg/4 mL	10 vials	70121-1754-7
400 mg/16 mL	1 vial	70121-1755-1
400 mg/16 mL	10 vials	70121-1755-7

HCPCS code<sup>4</sup>: Q5126



FYLNETRA® (pegfilgrastim-pbbk)

Reference product: Neulasta® (pegfilgrastim)<sup>6</sup>

Description: Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg<sup>4</sup>

- Prefilled syringe<sup>6</sup>
- Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light<sup>6</sup>

Unit of sale <sup>6</sup>	Unit of sale quantity	NDC
6 mg/0.6 mL	1 prefilled syringe	70121-1627-1

HCPCS code<sup>4</sup>: Q5130



RELEUKO® (filgrastim-ayow)

Reference product: Neupogen® (filgrastim)<sup>7</sup>

Description: Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram<sup>4</sup>

- Extended shelf life of up to 24 months<sup>5</sup>
- Store refrigerated between 2°C to 8°C (36°F to 46°F)<sup>7</sup>

Unit of sale <sup>7</sup>	Unit of sale quantity	NDC
300 mcg/0.5 mL	1 prefilled syringe	70121-1568-1
300 mcg/0.5 mL	10 prefilled syringes	70121-1568-7
480 mcg/0.8 mL	1 prefilled syringe	70121-1570-1
480 mcg/0.8 mL	10 prefilled syringes	70121-1570-7

HCPCS code<sup>4</sup>: Q5125



FOCINVEZ™ (fosaprepitant injection)

Description: Injection, fosaprepitant (focinvez), 1 mg<sup>4</sup>

- A ready-to-use IV solution, without the need for dilution or reconstitution<sup>9</sup>
- Administered directly from the vial using included vial hanger<sup>9</sup>
- Shelf stable for up to 90 days at room temperature<sup>9</sup>

Unit of sale <sup>9</sup>	Unit of sale quantity	NDC
150 mg/50 mL	Single-dose vial	70121-2631-1

HCPCS code<sup>4</sup>: J1434



PEMRYDI RTU® (pemetrexed injection)

Description: Injection, pemetrexed (pemrydi rtu), 10 mg<sup>4</sup>

- No reconstitution or dilution needed<sup>10</sup>
- Stable at room temperature in original packaging<sup>10</sup>
- Withdraw the calculated dose from the vial(s) and transfer to an empty IV bag<sup>10</sup>

Unit of sale <sup>10</sup>	Unit of sale quantity	NDC
100 mg/10 mL	Single-dose vial	70121-2453-1
500 mg/50 mL	Single-dose vial	70121-2461-1

HCPCS code<sup>4</sup>: J9324



BORUZU® (bortezomib injection)

Description: Injection, bortezomib (boruzu), 0.1 mg<sup>11</sup>

- A ready-to-use presentation of bortezomib for subcutaneous administration<sup>12</sup>
- Does not require reconstitution<sup>12</sup>
- Store BORUZU® refrigerated at 2°C to 8°C (36°F to 46°F) in original package to protect from light<sup>12</sup>

Unit of sale <sup>12</sup>	Unit of sale quantity	NDC
3.5 mg/1.4 mL	Single-dose vial	70121-2484-1

HCPCS code<sup>11</sup>: J9054



# Scan QR code for more information



**AlymSYS**<sup>®</sup>  
(bevacizumab-maly)



**Fylnetra**<sup>®</sup>  
(pegfilgrastim-pbbk)



**Releuko**<sup>®</sup>  
(filgrastim-ayow)



**FOCINVEZ**<sup>™</sup>  
(fosaprepitant injection)



**PEMRYDI RTU**<sup>®</sup>  
(pemetrexed injection)



**BORUZU**<sup>®</sup>  
(bortezomib injection)

**References:** **1.** Amneal Pharmaceuticals. 2023 Amneal environmental, social and governance report. June 2024. Accessed Nov. 23, 2024. <https://amneal.com/wp-content/uploads/2023/06/Amneal-ESG-report-2022.pdf> **2.** Amneal Pharmaceuticals. 2022 Amneal environmental, social and governance report. June 2023. Accessed November 23, 2024. <https://amneal.com/wp-content/uploads/2023/06/Amneal-ESG-report-2022.pdf> **3.** ALYMSYS. Prescribing information. Amneal Pharmaceuticals LLC; 2022. **4.** Centers for Medicare & Medicaid Services. First quarter, 2025 HCPCS quarterly update. December 17, 2024. Accessed January 14, 2025. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update> **5.** Data on file. Amneal Pharmaceuticals. **6.** FYLNETRA. Prescribing information. Amneal Pharmaceuticals LLC; 2022. **7.** RELEUKO. Prescribing information. Amneal Pharmaceuticals LLC; 2022. **8.** US Food and Drug Administration. Overview of the 505(b)(2) regulatory pathway for new drug applications. Accessed November 23, 2024. <https://www.fda.gov/media/156350/download> **9.** FOCINVEZ. Prescribing information. Amneal Pharmaceuticals LLC; 2023. **10.** PEMRYDI RTU. Prescribing information. Amneal Pharmaceuticals LLC; 2024. **11.** Centers for Medicare & Medicaid Services. Fourth quarter, 2024 HCPCS coding cycle. Accessed January 14, 2025. <https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-4-2024-drugs-and-biologicals.pdf> **12.** BORUZU. Prescribing information. Amneal Pharmaceuticals LLC; 2024.

## amnealbiosciences.com | amneal.com

BORUZU<sup>®</sup> is approved by the US Food and Drug Administration but is not yet available for distribution.

ALYMSYS<sup>®</sup> is a registered trademark of mAbxience Research, S.L.

BORUZU<sup>®</sup> and PEMRYDI RTU<sup>®</sup> are registered trademarks of Amneal Pharmaceuticals LLC.

FOCINVEZ<sup>™</sup> is a pending trademark of Amneal Pharmaceuticals LLC.

RELEUKO<sup>®</sup> and FYLNETRA<sup>®</sup> are registered trademarks of Kashiv BioSciences, LLC.

Amneal Biosciences is a division within Amneal's Generics segment, which is a part of Amneal Pharmaceuticals LLC.

©2025 Amneal Pharmaceuticals LLC. All rights reserved. PP-ADP-BIOSC-US-0012 01/25

